Full year revenues expected to treble at Retroscreen Virology Group

AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.

AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.

The company expects to report sales for the year ending December 31st 2012 in excess of £13m compared to £4.27m for the twelve months until December 31st 2011. Gross margin and net loss are also expected to be ahead of market expectations.

The trading update published by the company stated that significant revenue growth was being achieved from Retroscreen's solid pipeline of Viral Challenge Model (VCM) client engagements.

More specifically, it added that: "The revenue growth is principally due to the increased number of quarantines conducted during 2012, together with the study set-up and volunteer recruitment for a number of new VCM engagements with quarantines due to commence in 2013."

Kym Denny, Chief Executive Officer at Retroscreen Virology Group, commented, "I am thrilled by our revenue growth and delivery against a robust VCM pipeline, which continues to build steadily with clients holding firm against their VCM quarantine reservations booked months ahead."

Denny added: "Retroscreen remains focussed on revenue growth, developing capacity and pioneering the VCM as a new way to conducting clinical trials in the development of drugs against virus. We are building solid foundations to scale our growth and it is tremendously fulfilling to see that the outcome of this investment will be reported in our 2012 financial results."

Retroscreen Virology Group's share price rose 8.16% to 132.50p at 09:17 on Wednesday morning.

MF

Recommended

Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares in the week ending 5 August, providing an insight into how investors are thinking and where opportunities may l…
9 Aug 2022
Where to find inflation-resistant stocks
Investment strategy

Where to find inflation-resistant stocks

Terry Smith’s latest update contains some valuable pointers for investors looking to protect against inflation.
8 Aug 2022
A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022